COMMUNIQUÉS West-GlobeNewswire

Onco360® Has Been Selected as a Specialty Pharmacy Partner for INLURIYO™ (imlunestrant)
06/10/2025
LOUISVILLE, Ky., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Eli Lilly for Inluriyo™ (imlunestrant), indicated for the [...]
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
06/10/2025
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies [...]
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
06/10/2025
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data [...]
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
06/10/2025
- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects - - Pre-ESGCT meeting [...]
PBC Biomed Appoints Mark McMahan as Chief Commercial Officer
06/10/2025
SHANNON, Ireland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Irish medical device company PBC Biomed today announced the appointment of Mark McMahan as Chief Commercial Officer, effective October 2025. McMahan, formerly Vice [...]
Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers
06/10/2025
Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers Financing round led by IQ [...]
Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment
06/10/2025
Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment Proprietary MISBA Duo technology is the first platform to enable simultaneous, controlled upregulation [...]
Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025
06/10/2025
Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findings On track for full data read out in the first half of 2026 Discovery and preclinical data on O3R-5671 selected for oral presentation [...]
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
06/10/2025
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved [...]
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
06/10/2025
ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic [...]
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
06/10/2025
Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program [...]
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
06/10/2025
LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease [...]
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
06/10/2025
LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare [...]
Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions
06/10/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 October 2025 – 7:00 AM CET Fagron receives Brazilian antitrust clearance for Purifarma and Injeplast acquisitions Fagron, the [...]
Nyxoah Annonce les Premiers Patients Commerciaux Aux États-Unis Implantés avec le Système Genio®
06/10/2025
Nyxoah Annonce les Premiers Patients Commerciaux Aux États-Unis Implantés avec le Système Genio® Le lancement commercial initial témoigne d'une forte demande de la part des médecins, de préautorisations concluantes et d [...]
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System
06/10/2025
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage Mont-Saint-Guibert [...]
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel
06/10/2025
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function. This tool will be launched as part of Roche’s [...]
VALNEVA Déclaration d’actions et de droits de vote : 30 septembre 2025
06/10/2025
VALNEVA Déclaration d’actions et de droits de vote 30 septembre 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 [...]
VALNEVA Declaration of shares and voting rights: September 30, 2025
06/10/2025
VALNEVA Declaration of shares and voting rights September 30, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard [...]

Pages